Fresh Tracks Therapeutics(US:FRTX)2022-03-15 18:39Financial Data and Key Metrics Changes - The company reported cash and cash equivalents of $26.9 million as of December 31, 2021, which is expected to support operations beyond the receipt of Phase 1 results for BBI-02 anticipated by year-end 2022 [19] - Revenue for Q4 2021 was approximately $140,000, an increase from $27,000 in Q4 2020, primarily from royalty revenue [20] - R&D expenses for Q4 2021 were $3.1 million, down from $4.6 million in Q4 2020, mainly due to a reduction in clinical costs related to SB gel [20] - The net loss for Q4 2021 was $6.1 million, compared to $7.4 million for Q4 2020 [21] - For the full year 2021, revenue was $0.4 million, down from $1.8 million in 2020, with the decrease attributed to a shift from collaboration revenue to royalty revenue [22] - R&D expenses for 2021 were $28.2 million, up from $11.2 million in 2020, driven by increased clinical costs for SB gel and development of STING inhibitors [23] - The net loss for 2021 was $39.5 million, compared to $20.9 million in 2020 [25] Business Line Data and Key Metrics Changes - The company is advancing its most advanced program, sofpironium bromide, which is NDA ready following positive Phase 3 clinical study results [9][10] - BBI-02, a DYRK1A inhibitor, is set to enter Phase 1 clinical trials in Canada in Q2 2022 [13] - The lead STING inhibitor, BBI-10, is in preclinical development, with significant reductions in pro-inflammatory cytokines observed [16] Market Data and Key Metrics Changes - The company has established a presence in immunology and inflammation through recent partnerships and pipeline expansions [7] - The STING inhibitor portfolio targets high unmet need diseases, with several established pharmaceutical companies investing in this area [15] Company Strategy and Development Direction - The company aims to broaden its strategic focus by expanding its pipeline in immunology and inflammation, with several near-term milestones expected in 2022 [26] - The company is evaluating options to maximize the commercial success of SB gel, including potential partnerships [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the NDA submission for SB gel, with no additional clinical studies required following the pre-NDA meeting with the FDA [53] - The company is optimistic about the positive feedback from patients in Japan regarding the product, despite some market challenges due to COVID-19 [60] Other Important Information - The company has acquired exclusive global rights to a portfolio of novel STING inhibitors and is engaged in research to optimize these compounds [15][17] - The company has a library of nearly 1,000 assets for potential screening and development [48] Q&A Session Summary Question: Details on the Phase 1 study design for BBI-02 - The Phase 1A study will involve 56 patients, while the Phase 1B will have at least 33 patients across three cohorts, with 30 to 40 patients in Part 2 [30] Question: Status of sofpironium bromide partnering discussions - The company is exploring various alternatives for partnering and has had encouraging conversations with multiple players [35] Question: Context of BBI-10 in relation to other STING inhibitors - The company believes its STING inhibitor is differentiated by its mechanism, although it is still early in development compared to competitors [39] Question: Expected trends in R&D expenses for 2022 - R&D expenses are expected to decrease as the company focuses on development-stage programs, with a slight increase anticipated as Phase 1 studies progress [41] Question: NDA submission components and readiness - The NDA preparation is on track, with a complete package ready for submission by mid-2022, and no additional clinical studies required [53]